Skip to main content

ImmunityBio, Inc.

For the period ended Jun 18, 2025. Filed Apr 30, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 18, 2025 · Filed Apr 30, 2025

IBRX$8.64+7.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒Filed by a Party other than the Registrant ☐

Check the Appropriate Box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Under §240.14a-12

ImmunityBio, Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

To our Stockholders:

We are pleased to invite you to attend the 2025 annual meeting of stockholders (the Annual Meeting) of ImmunityBio, Inc. to be held on Wednesday, June 18, 2025 at 9:30 a.m. Pacific Time, or at any adjournment or postponement thereof. The Annual Meeting will be a virtual meeting of stockholders. You will be able to attend the Annual Meeting and vote your shares via Internet Webcast atvirtualshareholdermeeting.com/IBRX2025 by entering the 16-digit control number (Control Number) included in our Notice of Internet Availability of Proxy Materials, on your proxy card, or in the instructions that accompanied your proxy materials. Questions will need to be submitted prior to the Annual Meeting. To submit questions, please visit proxyvote.comwith your 16 digit Control Number. You will not be able to attend the Annual Meeting in person.

We have elected to provide access to our proxy materials over the Internet under the United States Securities and Exchange Commission’s (SEC) “notice and access” rules. We believe these rules allow us to provide you with the information you need while reducing our delivery costs and the environmental impact of the Annual Meeting. The board of directors (Board) has fixed the close of business on April 21, 2025 as the record date (Record Date) for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting and at any adjournment or postponement thereof. Our Notice of Internet Availability of Proxy Materials is being mailed to stockholders entitled to vote at the meeting on or about May 1, 2025.

Your vote is important. Whether or not you expect to attend the Annual Meeting via Internet Webcast, please vote at your earliest convenience. You may vote over the Internet, by telephone or, if you request to receive printed proxy materials, by mailing a proxy or voting instruction form. You may also vote your shares during the Annual Meeting. Submitting your proxy in advance of the Annual Meeting will not prevent you from voting your shares at the Annual Meeting, as your proxy is revocable at your option as described in the proxy statement accompanying this notice. Please review the instructions regarding each of your voting options described in the proxy statement, as well as in the Notice of Internet Availability of Proxy Materials or proxy card you received by mail.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The accompanying proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (Annual Report) are available to view and download atproxyvote.com.

Thank you for your ongoing support of, and continued interest in, ImmunityBio, Inc.

Sincerely,

Richard Adcock

Chief Executive Officer and President

April 29, 2025

ImmunityBio, Inc.

3530 John Hopkins Court San Diego, CA 92121

Office: +1-844-696-5235 Email: info@ImmunityBio.com

Notice of Annual Meeting of Stockholders

Date and Time:Wednesday, June 18, 2025 at 9:30 a.m. Pacific Time.
Internet Availability ofProxy Materials:Under rules adopted by the SEC, we may furnish proxy materials, including this proxy statement and our Annual Report by providing access to such documents on the Internet instead of mailing printed copies. Most of you will not receive printed copies of the proxy materials unless you request them. Instead, the Notice of Internet Availability of Proxy Materials, which is being mailed to stockholders on or about May 1, 2025, will instruct you as to how you may access and review all of the proxy materials on the Internet. The Notice of Internet Availability of Proxy Materials also instructs you as to how you may submit your proxy on the Internet. If you would like to receive printed copies of our proxy materials by mail, please follow the instructions in the Notice of Internet Availability of Proxy Materials for requesting such materials. If you request printed copies of the proxy materials by mail, the materials you receive will include the proxy card or voting instruction form for the Annual Meeting. A copy of our proxy statement and our Annual Report are also posted on proxyvote.com, and are available from the SEC on its website at sec.gov.
Webcast Address:virtualshareholdermeeting.com/IBRX2025
Items of Business:1.To elect eight directors from the nominees named in the accompanying proxy statement to serve until our 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier resignation or removal.2.To approve the ImmunityBio, Inc. 2025 Equity Incentive Plan (2025 Plan). 3.To ratify the selection of Deloitte & Touche LLP as ImmunityBio’s independent registered public accounting firm for the fiscal year ending December 31, 2025.4.To transact other business that may properly come before the Annual Meeting.
Record Date:Only stockholders of record of our common stock as of the close of business on Wednesday, April 21, 2025, are entitled to receive notice of, and vote at the Annual Meeting and any continuation, postponement, or adjournment thereof.
Meeting Admission:You are invited to attend the Annual Meeting via Internet Webcast if you are a stockholder of record or a beneficial owner of shares of our common stock, in each case, as of April 21, 2025. You will be able to attend the Annual Meeting via Internet Webcast at virtualshareholdermeeting.com/IBRX2025 by entering the 16-digit Control Number included in our Notice of Internet Availability of Proxy Materials, on your proxy card, or in the instructions that accompanied your proxy materials.

By Order of the Board of Directors,

Jason Liljestrom

Corporate Secretary

San Diego, California

April 29, 2025

Table of Contents
Page
PROXY STATEMENT1
Questions and Answers about the Proxy Materials and Annual Meeting1
PROPOSAL 1 – ELECTION OF DIRECTORS7
Nominees for Director7
Board Recommendation7
Director Biographies8
CORPORATE GOVERNANCE13
Composition of the Board13
Board Leadership Structure14
The Board’s Role in Risk Oversight15
Board Meetings15
Communication with the Board15
Board Committees and Charters16
Audit Committee16
Compensation Committee17
Nominating and Corporate Governance Committee18
Related Party Transaction Committee18
Special Committee18
Process for Selecting Directors and Director Qualifications19
Director Independence19
Prohibited Trading Activities20
Compensation Committee Interlocks and Insider Participation20
PROPOSAL 2 – APPROVAL OF THE IMMUNITYBIO, INC. 2025 EQUITY INCENTIVE PLAN21
Board Recommendation29
EXECUTIVE COMPENSATION29
Our Current Named Executive Officers29
Processes and Procedures for Executive Compensation29
Employment Arrangements with Our Current Named Executive Officers30
2024 Bonus Plan31
Merger or Change in Control32
Other Compensation Policies32
Tax and Accounting Considerations32
Executive Compensation Clawback Policy33
EXECUTIVE COMPENSATION TABLES33
Summary Compensation Table33
All Other Compensation – Other Compensation and Perquisites34
Grants of Plan-Based Awards35
Outstanding Equity Awards at Fiscal Year-End37
Option Exercises and Stock Vested38
EQUITY COMPENSATION PLAN INFORMATION38
DIRECTOR COMPENSATION39
2024 Director Compensation Policy39
Other Compensation Details39

i

Equity Awards40
Non-Employee Director Stock Ownership Policy40
Director Compensation Table41
PAY VERSUS PERFORMANCE42
Pay Versus Performance Table42
Narrative Disclosure to Pay Versus Performance Table43
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT44
PROPOSAL 3 – RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS46
Board Recommendation46
AUDIT MATTERS47
Audit Committee Report47
Fees Paid to Independent Registered Public Accounting Firm48
CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS48
Cambridge Investment49
Related-Party Debt50
Other Related-Party Agreements and Arrangements60
Indemnification Agreements64
Policies for Approval of Related-Party Transactions65
OTHER MATTERS65
Stockholder Proposals for the 2026 Annual Meeting65
Availability of Bylaws66
Code of Global Business Conduct and Ethics66
Insider Trading Policies and Procedures67
Policies and Practices Related to the Grant of Certain Equity Awards67
Householding of Proxy Materials67
No Incorporation by Reference67
APPENDIX A: IMMUNITYBIO, INC. 2025 EQUITY INCENTIVE PLANA-1

ii

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.